- Home
- QUAD vs INZY Comparison
QUAD vs INZY Comparison
Compare QUAD & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QUAD
- INZY
- Stock Information
- Founded
- QUAD 1971
- INZY 2015
- Country
- QUAD United States
- INZY United States
- Employees
- QUAD N/A
- INZY N/A
- Industry
- QUAD Publishing
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- QUAD Consumer Discretionary
- INZY Health Care
- Exchange
- QUAD Nasdaq
- INZY Nasdaq
- Market Cap
- QUAD 300.6M
- INZY 256.3M
- IPO Year
- QUAD 2010
- INZY 2020
- Fundamental
- Price
- QUAD $5.52
- INZY $4.00
- Analyst Decision
- QUAD Strong Buy
- INZY Buy
- Analyst Count
- QUAD 2
- INZY 9
- Target Price
- QUAD $9.45
- INZY $15.22
- AVG Volume (30 Days)
- QUAD 254.6K
- INZY 1.3M
- Earning Date
- QUAD 07-29-2025
- INZY 08-05-2025
- Dividend Yield
- QUAD 5.37%
- INZY N/A
- EPS Growth
- QUAD N/A
- INZY N/A
- EPS
- QUAD N/A
- INZY N/A
- Revenue
- QUAD $2,646,800,000.00
- INZY N/A
- Revenue This Year
- QUAD N/A
- INZY N/A
- Revenue Next Year
- QUAD N/A
- INZY N/A
- P/E Ratio
- QUAD N/A
- INZY N/A
- Revenue Growth
- QUAD N/A
- INZY N/A
- 52 Week Low
- QUAD $4.06
- INZY $0.72
- 52 Week High
- QUAD $9.13
- INZY $6.24
- Technical
- Relative Strength Index (RSI)
- QUAD 50.64
- INZY 83.61
- Support Level
- QUAD $5.22
- INZY $3.94
- Resistance Level
- QUAD $5.71
- INZY $3.97
- Average True Range (ATR)
- QUAD 0.18
- INZY 0.01
- MACD
- QUAD 0.00
- INZY -0.10
- Stochastic Oscillator
- QUAD 59.18
- INZY 70.67
About QUAD Quad Graphics Inc
Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.